Category Archives: Uncategorized

Apeiron team will attend AACR 2023 in Orlando, FL on April 18th 2023. Dr. James D. Joseph, Executive Director of biology will present our latest research on targeting the mitotic kinesin, KIF18A, in chromosomally unstable cancers. Dr. Fred Aswad, SVP of biology and Dr. Minghua Wang, Director of AIDD will be available to meet with […]

Combines precision oncology platform with single-cell sequencing and transcriptomics with aim to select patients most likely to benefit from GTAEXS-617 therapy Confirmed and identified CDK7-specific pharmacodynamic biomarkers in cancer and immune cells Phase 1/2 clinical trial to validate correlation of signature and response expected to commence in 1H 2023 following planned CTA submission in 4Q […]

GT Apeiron Therapeutics (‘Apeiron’) announced it has completed a $17.5 million Series A financing. Panacea Venture led the investment round with participation from Viva BioInnovator and existing investors. This is the company’s second round of financing in the last year following a Pre-A+ round in May 2021. The investment will enable the company to advance […]

Dr. Fred Aswad, SVP of Biology at Apeiron will present preclinical data on GTAEXS617, a novel, orally bioavailable, selective small-molecule inhibitor of CDK7 discovered using AI-driven drug discovery. GTAEXS617 is currently in IND-enabling studies. Preclinical data demonstrates that GTAEXS617 has favorable drug like properties and exhibits potent anti-tumour activity in HGSOC and TNBC xenograft tumour-bearing […]

On March 16, 2022, Apeiron’s Board of Directors have come to this decision to promote Dr. Fred Aswad and Dr. Xiao-hui Gu as Senior Vice President, reporting to Dr. Mingxi Li, CEO of Apeiron. The promotions were made in recognition of their contributions discovering and developing GTAEXS617, a selective CDK7 inhibitor. Earlier this month, we […]

Combines Exscientia’s leading AI-driven drug identification and design capabilities with GT Apeiron’s expertise in cyclin-dependent kinase (CDK) targets for oncology Expands existing CDK7 drug discovery partnership with additional CDK targeting drugs    Oxford & Shanghai – July 21st, 2021 – Exscientia, an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and […]

Keith Lenden and Dr. Honggang Bi has been appointed as new members of the Advisory Board at GT Apeiron Therapeutics, an AI empowered drug discovery start-up developing oncology therapeutics. Mr. Lenden and Dr. Bi add further expertise in drug discovery innovation, translational medicine, and clinical development; and deep knowledge and perspectives from both USA and Asia-Pacific region, to the Company’s Advisory Board. Mr. Keith […]

Apeiron Therapeutics opens US headquarter in the San Francisco Bay Area. The Bay Area office will enable Apeiron to tap into the deep expertise and talent pool at the intersection of biotechnology and artificial intelligence in the Bay Area and in the broader US. Fred Aswad, Ph.D., J.D., and Vice President of Biology will lead […]

GT Healthcare Capital Partners (“GT Healthcare”), a life science-focused private equity partnership which specializes in capital investments and market scalability in Asia/ Greater China region, has launched an AI-driven drug development company in SHANGHAI, June 1, 2019— GT Apeiron Therapeutics (“Apeiron Therapeutics”) SHANGHAI, June 1st, 2019 GT Healthcare Capital Partners (“GT Healthcare”)has launched an AI-driven […]

Apeiron Therapeutics is pleased to announce its partnership with Exscientia to accelerate the drug discovery process on several targets in oncology. Details of the deal are not disclosed at this time.